Oncosnacks 12: Enfortumab Vedotin skin toxicity management

On this episode, their final of 2023, Michael and Josh return to the world of recent fan favourite, enfortumab vedotin (EV). Not content to sing its praises from every rooftop, our intrepid hosts take the necessary step of examining the common and sometimes severe manifestations of dermatological toxicity deriving from EV. With the assistance of a recently published guideline, they examine the presentation, assessment and management of skin toxicity.

From all of us at OftiM, we would like to thank you for joining us throughout 2023, and we wish you a very happy festive season.

Useful Links:

Guideline ( et al, 2023): https://onlinelibrary.wiley.com/doi/full/10.1111/jdv.19454

CTCAE 5.0 guidelines for skin toxicity: https://www.researchgate.net/figure/Folliculitis-example-of-an-existing-toxicity-in-CTCAE_fig3_323714281

For more episodes, resources and blog posts, visit www.inquisitiveonc.com

Find us on Twitter @InquisitiveOnc!

If you want us to look at a specific trial or subject, email us at [email protected]

Art courtesy of Taryn Silver

Music courtesy of Music Unlimited: https://pixabay.com/users/music_unlimited-27600023/

Disclaimer: This podcast is for educational purposes only. If you are unwell, seek medical advice.

Hosted on Acast. See acast.com/privacy for more information.